Advances and highlights in biomarkers of allergic diseases

Öğülür, İsmail; Pat, Yağız; Ardicli, Ozge; Barletta, Elena; Cevhertas, Lacin; Fernandez, Tahía D.; Huang, Mengting; Imam, Manal Bel; Koch, Jana; Ma, Siyuan; Maurer, Debbie J; Mitamura, Yasutaka; Peng, Yaqi; Radzikowska, Urszula; Rinaldi, Arturo; Rodríguez-Coira, Juan; Satitsuksanoa, Pattraporn; Schneider, Stephan R; Wallimann, Alexandra; Zhakparov, Damir; Ziadlou, Reihane; Brüggen, Marie‐Charlotte; Veen, Willem van de; Sokołowska, Milena; Baerenfaller, Katja; Zhang, Luo; Akdiş, Mübeccel

doi:10.1111/all.15089

Cited by 122 publications

(76 citation statements)

References 224 publications

(585 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Atopic dermatitis (also known as atopic eczema), food allergies, asthma, and allergic rhinitis are the most common allergy-related diseases with similar epigenetic and physiopathological characteristics [ 22 , 23 ]. Numerous experimental and clinical studies have shown that the poor prognosis of atopic dermatitis and food allergies in early life greatly exacerbates the occurrence of later asthma and allergic rhinitis [ 1 – 4 , 24 ].…”

Section: Discussionmentioning

confidence: 99%

Network Pharmacology and Molecular Docking Study of Yupingfeng Powder in the Treatment of Allergic Diseases

Tao

2022

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

Objective. To explore the potential mechanisms of Yupingfeng Powder (YPFP) in the treatment of allergic diseases by using network pharmacology and molecular docking technology. Methods. The active components and targets of YPFP were screened by the TCMSP database. The targets associated with atopic dermatitis, asthma, allergic rhinitis, and food allergy were obtained from GeneCards and OMIM databases, respectively. The intersection of the above disease-related targets was identified as allergy-related targets. Then, allergy-related targets and YPFP-related targets were crossed to obtain the potential targets of YPFP for allergy treatment. A protein-protein-interaction (PPI) network and a drug-target-disease topology network were constructed to screen hub targets and key ingredients. Next, GO and KEGG pathway enrichment analyses were performed separately on the potential targets and hub targets to identify the biological processes and signaling pathways involved. Finally, molecular docking was conducted to verify the binding affinity between key ingredients and hub targets. Results. In this study, 45 active ingredients were identified from YPFP, and 48 allergy-related targets were predicted by network pharmacology. IL6, TNF, IL1B, PTGS2, CXCL8, JUN, CCL2, IL10, IFNG, and IL4 were screened as hub targets by the PPI network. However, quercetin, kaempferol, wogonin, formononetin, and 7-O-methylisomucronulatol were identified as key ingredients by the drug-target-disease topological network. GO and KEGG pathway enrichment analysis indicated that the therapeutic effect of YPFP on allergy involved multiple biological processes and signaling pathways, including positive regulation of fever generation, positive regulation of neuroinflammatory response, vascular endothelial growth factor production, negative regulation of cytokine production involved in immune response, positive regulation of mononuclear cell migration, type 2 immune response, and negative regulation of lipid storage. Molecular docking verified that all the key ingredients had good binding affinity with hub targets. Conclusion. This study revealed the key ingredients, hub targets, and potential mechanisms of YPFP antiallergy, and these data can provide some theoretical basis for subsequent allergy treatment and drug development.

show abstract

Section: Discussionmentioning

confidence: 99%

Network Pharmacology and Molecular Docking Study of Yupingfeng Powder in the Treatment of Allergic Diseases

Tao

2022

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

show abstract

“…A review by Breiteneder et al found that some of them achieved a better classification of distinct phenotypes or endotypes and increased the necessity to use biomarkers for patient selection, prediction of results and monitoring [ 13 ]. Ogulur et al [ 14 ] stated that such biomarkers are valuable parameters as they make information on the disease endotypes, clusters, identification of treatment targets and monitoring of efficacy available. These powerful omics technologies, together with integrated data analysis, are useful in identifying clinical biomarkers; these, however, need to be precisely measured by solid and reproducible methods.…”

Section: Omicsmentioning

confidence: 99%

“…The search for novel biomarkers of allergic diseases resulted in promising biomarkers of type-2 allergic diseases, including sputum eosinophils, exhaled nitric oxide and serum periostin. Biomarkers such as pro-inflammatory mediators, eicosanoid molecules, epithelial barrier integrity and microbiota changes quantified in serum, exhaled air and body fluids are suitable for diagnosing and monitoring allergies and, particularly, the efficacy of AIT, also considering the perspective of the COVID-19 pandemic [ 14 ].…”

Section: Omicsmentioning

confidence: 99%

The Present and Future of Allergen Immunotherapy in Personalized Medicine

Ridolo

Incorvaia

Heffler

et al. 2022

JPM

View full text Add to dashboard Cite

Allergic diseases are particularly suitable for personalized medicine, because they meet the needs for therapeutic success, which include a known molecular mechanism of the disease, a diagnostic tool for that disease and a treatment that blocks this mechanism. A range of tools is available for personalized allergy diagnosis, including molecular diagnostics, treatable traits and omics (i.e., proteomics, epigenomics, metabolomics, transcriptomics and breathomics), to predict patient response to therapies, detect biomarkers and mediators and assess disease control status. Such tools enhance allergen immunotherapy. Higher diagnostic accuracy results in a significant increase (based on a greater performance achieved with personalized treatment) in efficacy, further increasing the known and unique characteristics of a treatment designed to work on allergy causes.

show abstract

“…Its direct role on epithelial cells and barrier function has yet to be described. TSLP blockers (Tezepelumab) could then represent an interesting option for future treatments [ 76 ].…”

Section: Type 2 Inflammatory Cytokines and Tslpmentioning

confidence: 99%

Cytokine Signature and Involvement in Chronic Rhinosinusitis with Nasal Polyps

Carsuzaa

Béquignon

Dufour

et al. 2021

IJMS

View full text Add to dashboard Cite

Cytokines are well known to play a central role in chronic rhinosinusitis with nasal polyps (CRSwNP), particularly in maintenance of the inflammatory response and the recruitment of eosinophils. The pathophysiological concepts concerning the involvement of inflammatory cytokines in CRSwNP have gradually evolved. Although the Th2 cytokines environment associated with an eosinophilic infiltration has retained a central role in the genesis of polyps, the role of other cytokine subpopulations has also and more recently been detailed, leading to a specific and complex signature in CRSwNP. The purpose of this review is to summarize the current state of knowledge about the cytokine signature in CRSwNP, the role of cytokines in the pathogenesis of this disease and in the intercellular dialog between epithelial cells, fibroblasts and inflammatory cells. Knowledge of this precise cytokine signature in CRSwNP is fundamental in the perspective of potential targeting biotherapies.

show abstract

Advances and highlights in biomarkers of allergic diseases

Cited by 122 publications

References 224 publications

Network Pharmacology and Molecular Docking Study of Yupingfeng Powder in the Treatment of Allergic Diseases

Network Pharmacology and Molecular Docking Study of Yupingfeng Powder in the Treatment of Allergic Diseases

The Present and Future of Allergen Immunotherapy in Personalized Medicine

Cytokine Signature and Involvement in Chronic Rhinosinusitis with Nasal Polyps

Contact Info

Product

Resources

About